Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Failla Memorial Lecture. Redox, radiation, and reductive bioactivation.

G E Adams1

  • 1MRC Radiobiology Unit, Didcot, Oxfordshire, United Kingdom.

Radiation Research
|November 1, 1992
PubMed
Summary

Redox-sensitive drugs, including bioreductive agents and radiosensitizers, show promise in cancer therapy. Their efficacy is linked to electron affinity and selective toxicity to hypoxic tumor cells.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Treatment of Deciduous Molars.

International dental journal (Philadelphia, Pa.)·2023
Same author

Electron-affinic sensitization VII. A correlation between structures, one-electron reduction potentials, and efficiencies of nitroimidazoles as hypoxic cell radiosensitizers. 1976.

Radiation research·2012
Same author

31P magnetic resonance spectroscopy as a predictor of efficacy in photodynamic therapy using differently charged zinc phthalocyanines.

British journal of cancer·1999
Same author

Effect of serum starvation on expression and phosphorylation of PKC-alpha and p53 in V79 cells: implications for cell death.

International journal of cancer·1999
Same author

Indolequinone antitumor agents: reductive activation and elimination from (5-methoxy-1-methyl-4,7-dioxoindol-3-yl)methyl derivatives and hypoxia-selective cytotoxicity in vitro.

Journal of medicinal chemistry·1998
Same author

Magnetic resonance imaging and spectroscopy of combretastatin A4 prodrug-induced disruption of tumour perfusion and energetic status.

British journal of cancer·1998

Area of Science:

  • Oncology
  • Pharmacology
  • Biochemistry

Background:

  • Redox processes are crucial in cancer therapy, influencing radiosensitizers and bioreductive drugs.
  • Hypoxic cells in tumors present a therapeutic challenge due to resistance mechanisms.

Purpose of the Study:

  • To review the development and principles of redox-sensitive drugs for cancer treatment.
  • To describe the mechanisms of radiosensitizers and bioreductive drugs.
  • To highlight the potential of bioreductive agents as adjunct cancer therapies.

Main Methods:

  • Review of existing literature on redox-sensitive drugs and their mechanisms.
  • Analysis of the role of redox processes in drug activation and efficacy.
  • Description of various classes of bioreductive agents and their properties.

Main Results:

  • Redox-sensitive drugs, including radiosensitizers and bioreductive agents, exploit tumor hypoxia for selective action.
  • Drug potency correlates strongly with electron affinity.
  • Bioreductive drugs are activated by intracellular reduction, often favored under hypoxia, leading to differential cytotoxicity.

Conclusions:

  • Redox-sensitive drugs offer a rational approach to selective cancer therapy.
  • Bioreductive agents, such as nitroheterocycles and quinone-based drugs, are promising candidates for cancer treatment.
  • Further study of bioreductive agents could lead to novel adjunct therapies for various cancers.

Related Experiment Videos